Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company Limited
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque Psoriasis who are Naive to Systemic Treatment
The coprimary objectives of the study are to test whether ixekizumab Q2W/Q4W is superior to FAE and is superior to MTX at Week 24 in the treatment of patients with moderate-to-severe psoriasis who ar...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
To compare the effect of tadalafil 20 mg once a day for 12 weeks on detrusor pressure at peak urinary flow rate versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy
The primary objective of this study is to compare overall survival time following treatment with ALIMTA 500 mg/m2 versus ALIMTA 900 mg/m2 in patients with locally advanced or metastatic (Stage III or ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis
The primary objective of this study is to compare the effect of orally administered 20 mg arzoxifene daily versus orally administered 60 mg raloxifene daily on 12-month percent change from baseline in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia
The primary objective of this study is to evaluate whether OP Depot is superior to haloperidol decanoate in terms of overall effectiveness as measured by the time to all-cause discontinuation for up t...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer
The study will be conducted in 2 parts: • Part 1: a single-arm, unblinded, safety lead in. • Part 2: a multiple-site, randomized, double-blind, placebo-controlled study. The objective of the Safety l...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome
to assess the efficacy of duloxetine 60/120mg once daily (QD) compared with placebo on the treatment of pain in patients with American College of Rheumatology (ACR) defined primary fibromyalgia syndro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC
Evaluate progression free survival between Pemetrexed 500 mg/m² every 3 weeks + Erlotinib 150 mg daily and Pemetrexed 500 mg/m² every 3 weeks when given as second line therapy for the treatment of loc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy
To evaluate the efficacy of tadalafil 5 mg once a day (OAD) and tadalafil 20 mg on demand (PRN), compared with placebo, when taken orally over 9 months, in improving unassisted erectile function in me...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
Study of Prasugrel in Children who have Sickle Cell Disease
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Prasugrel Active Metabolite (Pras-AM) [ Time Frame: Parts A and B: 0.5, 1, 1.5, 2, 4 hours postdose ] •Percentage of Platel...
Country
None
organs
None
Specialty
None
More information
Previous
1
2
3
4
5
6
Next